Skip to main content

Advertisement

Table 1 Clinical studies of HIPEC in patients with peritoneal carcinomatosis from colorectal origin

From: BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis

Author N IP chemo (mg/m2) Mb (%) Mt (%) RR (%) HS (d) MS (m) prognostic variables in multivariate analysis
CRT
 Verwaal [16, 17] 49a MMC 35 - 8 - 29 22.3 >5/7 regions affected; CC
Multicentre
 Elias [22] 523b MMC 30–50, CIS 50–100 OX 360–460, IRN 200 31 3.3 - 18 30.1 PCI, CC, nodal status, adjuvant chemotherapy
 Glehen [18] 506c MMC, CIS, OX 23 4 10.7 - 19.2 PCI, CC, adjuvant chemotherapy, age <65y
 Hompes [20] 48 OX 460 52 0 21 20 NR -
 Cavaliere [21] 146 CIS 25, OX 460, MMC 33 27 2.7 - 20 21 CC, liver metastasis
 Quenet [23] 146 OX 300–460, IRN 200 47 4 - - 41 PCI, nodal status
Monocentric
 Franko [24] 67 MMC 40 - - - - 35 -
 Cashin [25] 69 MMC 30, OX 460, IRN 360 40.6 4.3 - - 34 -
 Shen [26] 77 MMC 30-40 30 12 - 10 16 CC, bowel obstruction, ascites
 Vaira [27] 40 CIS 100, MMC 16–35, OX 460 55 2.5 23 - - -
 Ceelen [28] 166 OX 200–460, MMC 35 35 2.4 - - 27 CC, neoadjuvant therapy with BEV
  1. BEV bevacizumab, CC completeness of cytoreduction, CIS cisplatin, HIPEC hyperthermic intraperitoneal chemoperfusion, HS hospital stay, IP intraperitoneal, IRN irinotecan; Mb postoperative morbidity, MMC mitomycin C; MS median survival in months, Mt postoperative mortality, NR not reached, OX oxaliplatin, PCI peritoneal cancer index, RR reoperation rate; aincludes 13 % appendix cancer; b18 % early postoperative intraperitoneal chemotherapy (EPIC) alone; c24 % EPIC alone